Department of Laboratory Medicine, Cross Cancer Institute and University of Alberta, Edmonton, Canada.
Am J Clin Pathol. 2010 Jan;133(1):149-55. doi: 10.1309/AJCP1FNW7RGZFTYU.
Mutational analysis of c-KIT or PDGFRA has become an important laboratory assay for patients with gastrointestinal stromal tumors (GISTs) because the results are useful in predicting the responsiveness to imatinib. To assess the diagnostic usefulness of denaturing high-pressure liquid chromatography (DHPLC) in this setting, we performed DHPLC and DNA sequencing to study exons 9, 11, 13, and 17 of c-KIT and exons 12 and 18 of PDGFRA in 54 consecutive cases of GIST collected from a single population. Most (40/54 [74%]) carried c-KIT mutations, and 7 (13%) carried PDGFRA mutations. These results were similar to those described in the literature. It is important to note that DHPLC was found to be highly sensitive, detecting all of the mutations in these 6 exons that were identified by DNA sequencing. Our data suggest that DHPLC is a cost-effective, rapid, and sensitive test for screening for mutations of c-KIT and PDGFRA in GISTs.
对胃肠道间质肿瘤(GIST)患者进行 c-KIT 或 PDGFRA 的突变分析已成为一项重要的实验室检测,因为其结果有助于预测伊马替尼的反应性。为了评估变性高压液相色谱(DHPLC)在这种情况下的诊断效用,我们对从单一人群中收集的 54 例连续 GIST 病例的 c-KIT 的外显子 9、11、13 和 17 以及 PDGFRA 的外显子 12 和 18 进行了 DHPLC 和 DNA 测序研究。大多数(40/54 [74%])存在 c-KIT 突变,7 例(13%)存在 PDGFRA 突变。这些结果与文献中的描述相似。值得注意的是,DHPLC 被发现具有高度的敏感性,能够检测到通过 DNA 测序鉴定的这 6 个外显子中的所有突变。我们的数据表明,DHPLC 是一种经济有效、快速和敏感的检测 GIST 中 c-KIT 和 PDGFRA 突变的方法。